To receive CME credit for this program:
- Read the CME information and mark the checkbox confirming you have read the disclosures to download the PDF file below
- Review the article and illustration
- Login or register at the CME post test website (http://www.bucmetest.com)
- Locate the course code I.ANG11RCCBRST and take the test
Jointly sponsored by Boston University School of Medicine and the Angiogenesis Foundation
ACCREDITATION STATEMENT
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through Joint Sponsorship of Boston University School of Medicine and the Angiogenesis Foundation. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Boston University School of Medicine designates this Internet activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit will be awarded provided this activity is used and completed according to instructions and a score of 70% or better is achieved. A certificate of credit will be issued to those who successfully complete the examination.
RELEASE AND EXPIRATION
Date of original release: July 30, 2011
Date of expiration: July 29, 2012
Estimated Time To Complete: 1.5 Hours
CME Course Code: I.ANG11RCCBRST
TARGET AUDIENCE
Practicing oncologists in the U.S., researchers and medical students
HEALTHCARE GAP
Antiangiogenic therapy represents a relatively new approach to cancer management. There is a critical need to rapidly and effectively educate physicians about the scientific and clinical rationale for treating tumor angiogenesis; the pathways and mechanisms involved in tumor angiogenesis; the strategies by which antiangiogenic agents are being integrated into traditional therapeutic protocols; the efficacy and safety data emerging from well-designed and rigorous clinical studies of antiangiogenic therapy; and how this data can directly be used to improve clinical decision-making and outcomes for cancer patients.
In metastatic breast cancer (mBC), an FDA advisory panel has recommended revoking the bevacizumab label for this indication. However, in all likelihood, this antiangiogenic agent will continue to be used and reimbursed for the treatment of mBC. There is an unmet need for a comprehensive, evidence-based review of the clinical data bevacizumab for mBC in light of these recent developments. Further, a critical need exists to educate oncologists about strategies that may increase the degree of the anti-tumor effects with the hope of inducing more complete responses impeding the onset of or elimination of refractory disease. Combinations of these and other targeted agents may overcome the resistance that develops with single-agent therapy and could be incorporated either as part of initial therapy or later when disease resistance develops.
In advanced renal cell carcinoma (RCC), new treatments have extended survival for a proportion of patients who receive them. Nevertheless, most patients experience disease progression within a matter of months. Antiangiogenic therapies are changing the treatment landscape for this tumor type, and an urgent need exists to provide clinicians with up-to-date clinical efficacy and safety data on the use of these agents.
PROGRAM LEARNING OBJECTIVES
The overarching objective is to educate medical oncologists who have a high number of patients in their practice that could benefit from new treatments targeting tumor angiogenesis in cancer.
At the completion of this activity, participants should be able to:
- Describe the role of tumor angiogenesis as both a disease mechanism and therapeutic target in cancer.
- Discuss key efficacy data from clinical studies of combinations of chemotherapy and antiangiogenic agents for the treatment of mBC.
- Discuss key efficacy data from clinical studies combining anti-VEGF agents with anti-EGFR agents in the treatment for mBC.
- Interpret and differentiate between key endpoints in clinical studies of antiangiogenic agents for mBC.
- Explain the different tumor and angiogenic signaling pathways in RCC and how they can be targeted for therapy.
- Differentiate between the different targeted therapies for advanced RCC and discuss the clinical evidence supporting their use.
- Identify and discuss the management of adverse effects of antiangiogenic therapies.
- Describe the role of biomarkers to help stratify patients for therapy.
METHOD OF PARTICIPATION
There are no fees for participating in and receiving credit for this online educational activity. The participant should, in order, read the objectives and faculty disclosures, review the educational content, answer the multiple-choice post-test and complete the evaluation. This program is available in PDF format accessible from the Angiogenesis Foundation's website (http://www.angio.org) in the CME section. A print version is also available; for more information contact outreach@angio.org. After reviewing the material, CME credits are available through the Boston University School of Medicine's website (http://www.bucmetest.com) by selecting the name of the program (registration required). Course code: I.ANG11RCCBRST.
ACKNOWLEDGEMENT OF SUPPORT
This activity is supported by an educational grant from Genentech and Pfizer.
COURSE FACULTY
Roberto Pili, M.D.
Professor of Oncology
Chief, Genitourinary Section
Co-leader, Genitourinary Program, Department of Medicine
Roswell Park Cancer Institute
DISCLOSURE
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Roberto Pili, M.D., Roswell Park Cancer Institute
Faculty
Dr. Pili receives grant/research support from Regeneron and is a consultant for Genentech, Pfizer, and Regeneron.
William W. Li, M.D.,
President, the Angiogenesis Foundation, Editor-in-Chief
Dr. Li has nothing to disclose with regard to commercial interests.
Vickie R. Driver, DPM, M.S., FACFAS, Associate Professor of Surgery, Boston University School of Medicine
Course Director
Dr. Driver receives grant/research support from KCI, sanofi-aventis, 3M, and Baxter. She serves on the Scientific Steering Committee for sanofi-aventis.
Jody Walker, M.S.
BUSM CME Program Manager
BUSM CME Program Manager has nothing to disclose with regard to commercial interests.
Roderick A. Smith, M.S.
Medical Writer, Program Manager, the Angiogenesis Foundation
Medical Writer, Program Manager has nothing to disclose with regard to commercial interests.
DISCUSSION OF UNLABELLED USE
This CME activity contains discussion of published and/or investigational use of: axitinib, bevacizumab (Avastin®), everolimus (Afinitor®), lapatinib (Tykerb®), pazopanib (Votrient®), sorafenib (Nexavar®), sunitinib (Sutent®), temsirolimus (Torisel®), tivozanib, and trastuzumab (Herceptin®).
PRIVACY POLICY
The Office of Continuing Medical Education adheres to Boston University’s Conditions of Use and Policy on Computing Ethics. <http://www.bu.edu/cme/policies/privacy_policy.html>
Data gathered from participants who participate in Boston University School of Medicine’s (BUSM) Continuing Medical Education Internet-Based CME program is confidential.
Individual identifiable information is not shared with outside parties. Cumulative data may be analyzed by CME personnel, and, upon occasion, by individuals external to BUSM CME in order to determine trends.
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLEY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKE NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
TOPICS AND EDUCATIONAL CONTENT
Mechanisms of action of antiangiogenic therapies for mBC and RCC; latest safety and efficacy data on the use of antiangiogenic therapies for cancer; management of side effects; information on ongoing clinical trials. Oncologists are incorporating targeted therapies into standard approved treatment regimens for their patients, and many are enrolling patients into clinical trials using targeted therapies. With dozens of targeted agents in advanced clinical trials for cancer, it is essential that oncologist become aware of these agents, their appropriate use, how they may interact with other treatments, and how to recognize and manage side effects.
SYSTEM REQUIREMENTS
This educational program is available in PDF format. To view and print PDF files, you must have Adobe Reader installed on your computer. Most computers already have this software installed. If yours does not, you can download Adobe Reader free from the Adobe Web site: http://www.adobe.com.
If you have questions regarding certificates, please contact BUSM CME by email at cme@bu.edu or visit http://www.bu.edu/cme
For questions about this program, please contact the Angiogenesis Foundation at 617-401-2779 or outreach@angio.org.
Copyright 2011 by the Angiogenesis Foundation. All rights reserved.
|
